carbachol has been researched along with Basal Ganglia Diseases in 2 studies
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wolfarth, S | 1 |
| Murphey, DL | 1 |
| Dill, RE | 1 |
1 review available for carbachol and Basal Ganglia Diseases
| Article | Year |
|---|---|
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; C | 1976 |
1 other study available for carbachol and Basal Ganglia Diseases
| Article | Year |
|---|---|
Dentatectomy: absence of effects on dyskinesias arizing from chemical stimulation of the striatum in rats.
Topics: Animals; Basal Ganglia Diseases; Carbachol; Cerebellar Nuclei; Corpus Striatum; Male; Movement Disor | 1972 |